METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY

Patent №

US 7,908,091

Granted

2011-03-15

Filed 2007

Owner

PROMETHEUS LABORATORIES INC.

Lab

AI components

1

planning

Assignment

Recorded

Dataset

AIPD

2023_r1 edition

Application

11687254

The present invention provides methods for analyzing a combination of biomarkers to individualize tyrosine kinase inhibitor therapy in patients who have been diagnosed with cancer. In particular, the assay methods of the present invention are useful for predicting, identifying, or monitoring the response of a tumor, tumor cell, or patient to treatment with a tyrosine kinase inhibitor using an algorithm based upon biomarker profiling. The assay methods of the present invention are also useful for predicting whether a patient has a risk of developing toxicity or resistance to treatment with a tyrosine kinase inhibitor. In addition, the assay methods of the present invention are useful for monitoring tyrosine kinase inhibitor therapy in a patient receiving the drug to evaluate whether the patient will develop resistance to the drug. Furthermore, the assay methods of the present invention are useful for optimizing the dose of a tyrosine kinase inhibitor in a patient receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects.

PlanningG16B 20/20A61P 35/00C12Q 1/6886G01N 33/5758G16B 20/00G16B 40/20C12Q 2600/106C12Q 2600/154+5 more

AI classification

Planning0.88
Machine learning0.40
Natural language0.01
Vision0.00
Evolutionary computation0.00
AI hardware0.00
Knowledge representation0.00
Speech0.00

Ownership

PROMETHEUS LABORATORIES INC.

assignment · 202080140

Assignors

HARVEY, JEANNE, NERI, BRUCE, SINGH, SHARAT

On an employer assignment, the assignors are typically the inventors.

© 2026 NYSGPT2525 LLC